Article

Rational Design of a Therapeutic Nanobody for the Direct Inhibition of the KRAS Oncoprotein

2025-07-30

Abstract excerpt

<title>Abstract</title> <p>The KRAS oncoprotein remains a therapeutic challenge due to the limitations of current covalent inhibitors. This work presents the rational design of PIAKRASv2-Nb, a 100% humanized nanobody generated via the Protein Interaction Architect (PIA) method, which binds the DEYDPTIEDS epitope in the Switch I region of KRAS with exceptional affinity (ipTM = 0.78). Unlike classical approaches, t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8db6c7e6-80a0-5d9d-a7db-c121484b33c3
DOI: 10.21203/rs.3.rs-7239936/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Rational Design of a Therapeutic Nanobody for the Direct Inhibition of the KRAS OncoproteinDOI 10.21203/rs.3.rs-7239936/v1Read

Rational ab initio Design of a Humanized Nanobody against KRAS using the PIA MethodSemantic proximity Read

Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.Semantic proximity Read

From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.Semantic proximity Read

Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment.Semantic proximity Read

AI-assisted protein design to rapidly convert antibody sequences to intrabodies targeting diverse peptides and histone modificationsSemantic proximity Read

Eliminating oncogenic RAS: back to the future at the drawing board.Semantic proximity Read

RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric siteSemantic proximity Read

Selective and noncovalent targeting of RAS mutants for inhibition and degradation.Semantic proximity Read

An integrated in silico-in vitro workflow for discovering high-affinity, selective antibodies to the KRAS(G12D)-MHC I complexSemantic proximity Read

KRAS inhibitors: going noncovalent.Semantic proximity Read

Atomistic Profiling of KRAS Interactions with Monobodies and Affimer Proteins Through Ensemble-Based Mutational Scanning Unveils Conserved Residue Networks Linking Cryptic Pockets and Regulating Mechanisms of Binding, Specificity and AllosterySemantic proximity Read

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.Semantic proximity Read